PRIVIA HEALTH GROUP INC (PRVA) Stock Fundamental Analysis
USA - NASDAQ:PRVA - US74276R1023 - Common Stock
24.45 USD
+0.13 (+0.53%)
Overall PRVA gets a fundamental rating of 4 out of 10. We evaluated PRVA against 100 industry peers in the Health Care Providers & Services industry. While PRVA has a great health rating, there are worries on its profitability. PRVA is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
PRVA had positive earnings in the past year.
PRVA had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: PRVA reported negative net income in multiple years.
Each year in the past 5 years PRVA had a positive operating cash flow.
1.2 Ratios
PRVA's Return On Assets of 1.34% is in line compared to the rest of the industry. PRVA outperforms 53.00% of its industry peers.
With a Return On Equity value of 2.56%, PRVA perfoms like the industry average, outperforming 58.00% of the companies in the same industry.
PRVA has a Return On Invested Capital (2.45%) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.34% | ||
| ROE | 2.56% | ||
| ROIC | 2.45% |
ROA(3y)0.83%
ROA(5y)-3.09%
ROE(3y)1.55%
ROE(5y)-3.63%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PRVA has a Profit Margin of 0.89%. This is comparable to the rest of the industry: PRVA outperforms 55.00% of its industry peers.
PRVA's Profit Margin has declined in the last couple of years.
PRVA has a Operating Margin of 1.38%. This is comparable to the rest of the industry: PRVA outperforms 45.00% of its industry peers.
PRVA's Operating Margin has declined in the last couple of years.
PRVA has a worse Gross Margin (10.17%) than 74.00% of its industry peers.
PRVA's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 1.38% | ||
| PM (TTM) | 0.89% | ||
| GM | 10.17% |
OM growth 3YN/A
OM growth 5Y-13.74%
PM growth 3YN/A
PM growth 5Y-4.5%
GM growth 3Y15.6%
GM growth 5Y3.18%
2. Health
2.1 Basic Checks
PRVA has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for PRVA has been increased compared to 1 year ago.
The number of shares outstanding for PRVA has been increased compared to 5 years ago.
There is no outstanding debt for PRVA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
PRVA has an Altman-Z score of 4.54. This indicates that PRVA is financially healthy and has little risk of bankruptcy at the moment.
PRVA has a better Altman-Z score (4.54) than 79.00% of its industry peers.
PRVA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 4.54 |
ROIC/WACC0.27
WACC9.13%
2.3 Liquidity
PRVA has a Current Ratio of 1.67. This is a normal value and indicates that PRVA is financially healthy and should not expect problems in meeting its short term obligations.
PRVA has a Current ratio of 1.67. This is in the better half of the industry: PRVA outperforms 61.00% of its industry peers.
PRVA has a Quick Ratio of 1.67. This is a normal value and indicates that PRVA is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.67, PRVA is in the better half of the industry, outperforming 65.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.67 | ||
| Quick Ratio | 1.67 |
3. Growth
3.1 Past
PRVA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 30.00%, which is quite impressive.
The Earnings Per Share has been growing slightly by 7.43% on average over the past years.
Looking at the last year, PRVA shows a quite strong growth in Revenue. The Revenue has grown by 19.01% in the last year.
PRVA shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 17.17% yearly.
EPS 1Y (TTM)30%
EPS 3YN/A
EPS 5Y7.43%
EPS Q2Q%66.67%
Revenue 1Y (TTM)19.01%
Revenue growth 3Y21.58%
Revenue growth 5Y17.17%
Sales Q2Q%-21.55%
3.2 Future
PRVA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 59.62% yearly.
Based on estimates for the next years, PRVA will show a small growth in Revenue. The Revenue will grow by 2.27% on average per year.
EPS Next Y53.99%
EPS Next 2Y72.31%
EPS Next 3Y59.62%
EPS Next 5YN/A
Revenue Next Year15.55%
Revenue Next 2Y8.04%
Revenue Next 3Y6.75%
Revenue Next 5Y2.27%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 188.08, which means the current valuation is very expensive for PRVA.
Based on the Price/Earnings ratio, PRVA is valued a bit more expensive than 60.00% of the companies in the same industry.
PRVA's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.35.
Based on the Price/Forward Earnings ratio of 74.86, the valuation of PRVA can be described as expensive.
PRVA's Price/Forward Earnings is on the same level as the industry average.
PRVA's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 33.72.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 188.08 | ||
| Fwd PE | 74.86 |
4.2 Price Multiples
PRVA's Enterprise Value to EBITDA ratio is a bit more expensive when compared to the industry. PRVA is more expensive than 61.00% of the companies in the same industry.
The rest of the industry has a similar Price/Free Cash Flow ratio as PRVA.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 27.11 | ||
| EV/EBITDA | 68.21 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates PRVA does not grow enough to justify the current Price/Earnings ratio.
A more expensive valuation may be justified as PRVA's earnings are expected to grow with 59.62% in the coming years.
PEG (NY)3.48
PEG (5Y)25.3
EPS Next 2Y72.31%
EPS Next 3Y59.62%
5. Dividend
5.1 Amount
PRVA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:PRVA (11/12/2025, 11:14:43 AM)
24.45
+0.13 (+0.53%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners97.09%
Inst Owner Change2.17%
Ins Owners1.85%
Ins Owner Change1.07%
Market Cap3.00B
Revenue(TTM)2.04B
Net Income(TTM)18.17M
Analysts84.62
Price Target32.19 (31.66%)
Short Float %3.28%
Short Ratio4.63
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-34.97%
Min EPS beat(2)-60.96%
Max EPS beat(2)-8.97%
EPS beat(4)0
Avg EPS beat(4)-37.14%
Min EPS beat(4)-60.96%
Max EPS beat(4)-8.97%
EPS beat(8)0
Avg EPS beat(8)-42.01%
EPS beat(12)3
Avg EPS beat(12)40.52%
EPS beat(16)6
Avg EPS beat(16)56.54%
Revenue beat(2)1
Avg Revenue beat(2)-10.75%
Min Revenue beat(2)-27.23%
Max Revenue beat(2)5.73%
Revenue beat(4)3
Avg Revenue beat(4)-3.21%
Min Revenue beat(4)-27.23%
Max Revenue beat(4)7.92%
Revenue beat(8)7
Avg Revenue beat(8)-0.25%
Revenue beat(12)9
Avg Revenue beat(12)-3.44%
Revenue beat(16)9
Avg Revenue beat(16)-11.9%
PT rev (1m)3.19%
PT rev (3m)3.12%
EPS NQ rev (1m)-7.21%
EPS NQ rev (3m)-11.08%
EPS NY rev (1m)1.84%
EPS NY rev (3m)-19.27%
Revenue NQ rev (1m)4.95%
Revenue NQ rev (3m)-3.99%
Revenue NY rev (1m)0%
Revenue NY rev (3m)3.39%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 188.08 | ||
| Fwd PE | 74.86 | ||
| P/S | 1.47 | ||
| P/FCF | 27.11 | ||
| P/OCF | 27.11 | ||
| P/B | 4.23 | ||
| P/tB | 8.12 | ||
| EV/EBITDA | 68.21 |
EPS(TTM)0.13
EY0.53%
EPS(NY)0.33
Fwd EY1.34%
FCF(TTM)0.9
FCFY3.69%
OCF(TTM)0.9
OCFY3.69%
SpS16.64
BVpS5.78
TBVpS3.01
PEG (NY)3.48
PEG (5Y)25.3
Graham Number4.11
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.34% | ||
| ROE | 2.56% | ||
| ROCE | 3.67% | ||
| ROIC | 2.45% | ||
| ROICexc | 5.77% | ||
| ROICexgc | N/A | ||
| OM | 1.38% | ||
| PM (TTM) | 0.89% | ||
| GM | 10.17% | ||
| FCFM | 5.42% |
ROA(3y)0.83%
ROA(5y)-3.09%
ROE(3y)1.55%
ROE(5y)-3.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5Y-10.22%
OM growth 3YN/A
OM growth 5Y-13.74%
PM growth 3YN/A
PM growth 5Y-4.5%
GM growth 3Y15.6%
GM growth 5Y3.18%
F-Score7
Asset Turnover1.51
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 112.37 | ||
| Cash Conversion | 296.89% | ||
| Profit Quality | 609.36% | ||
| Current Ratio | 1.67 | ||
| Quick Ratio | 1.67 | ||
| Altman-Z | 4.54 |
F-Score7
WACC9.13%
ROIC/WACC0.27
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)30%
EPS 3YN/A
EPS 5Y7.43%
EPS Q2Q%66.67%
EPS Next Y53.99%
EPS Next 2Y72.31%
EPS Next 3Y59.62%
EPS Next 5YN/A
Revenue 1Y (TTM)19.01%
Revenue growth 3Y21.58%
Revenue growth 5Y17.17%
Sales Q2Q%-21.55%
Revenue Next Year15.55%
Revenue Next 2Y8.04%
Revenue Next 3Y6.75%
Revenue Next 5Y2.27%
EBIT growth 1Y114.42%
EBIT growth 3YN/A
EBIT growth 5Y1.07%
EBIT Next Year534.36%
EBIT Next 3Y107.12%
EBIT Next 5Y64.83%
FCF growth 1Y142.02%
FCF growth 3Y26.09%
FCF growth 5Y42.42%
OCF growth 1Y141.5%
OCF growth 3Y25.67%
OCF growth 5Y35.01%
PRIVIA HEALTH GROUP INC / PRVA FAQ
What is the fundamental rating for PRVA stock?
ChartMill assigns a fundamental rating of 4 / 10 to PRVA.
What is the valuation status for PRVA stock?
ChartMill assigns a valuation rating of 2 / 10 to PRIVIA HEALTH GROUP INC (PRVA). This can be considered as Overvalued.
Can you provide the profitability details for PRIVIA HEALTH GROUP INC?
PRIVIA HEALTH GROUP INC (PRVA) has a profitability rating of 3 / 10.
What is the valuation of PRIVIA HEALTH GROUP INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for PRIVIA HEALTH GROUP INC (PRVA) is 188.08 and the Price/Book (PB) ratio is 4.23.
What is the earnings growth outlook for PRIVIA HEALTH GROUP INC?
The Earnings per Share (EPS) of PRIVIA HEALTH GROUP INC (PRVA) is expected to grow by 53.99% in the next year.